Day Three - ET (Eastern Time, GMT-05:00)
- Katelyn Reichheld - Conference Producer, Informa Connect
- Felecia Manning - Senior Director, Managed Markets Pricing & Government Programs, United Therapeutics Corporation
Identifying patient population size more accurately
Understanding the payer mix beyond claims data
Aligning sales targeting and tailored marketing messaging to IDN HCPs
Opening alternative distribution methods and partnerships with vendors
- Jerry Taglianetti - Vice President, Market Access, Loopback Analytics
- Jerry Buller, DPh, MMHC - Independent Consultant, .
- Lessons Learned from the First Round of CMS Negotiations
- Unique Considerations for Government Payer Engagement
- Comprehensive Guidance for Manufacturers: Preparing for Future Negotiations
- John Shakow - Partner, King & Spalding LLP
- IRA Final Rule timeline and implementation status
- 340B examined and alternative rebate model
- Chevron insights
- Post election modeling
- Medicaid final rule implementation
- Tom Evegan - Principal, National Consulting Leader, Life Sciences, RSM US LLP
- Alice Valder Curran - Partner, Global Regulatory, Hogan Lovells
- Trevor Wear - Partner, Sidley Austin LLP
- Christopher Schott - Partner, Latham & Watkins
- Stephanie Trunk - Partner, ArentFox Schiff LLP
- Margaux Hall - Partner, Ropes & Gray LLP
- Limited distribution network design
- Cold chain and handling requirements in contracts
- Performance metrics for specialty products
- Complex pricing model management
- Channel strategy optimization
- Haris Kamal - Chief Revenue Officer, Chronicled
- AI/ML implementation for contract management -Predictive analytics for pricing optimization
- Advanced reporting and dashboard development
- System integration automation
- Performance optimization through data analysis
- David Salazar - Associate Director of Contracts and Pricing, UCB Inc
Master evolving competitive dynamics between originators, biosimilars, and generics - examining real-world pricing strategies, PBM pressures, and channel optimization approaches across product types
Balance profitability amid complex government program requirements, wholesaler fee structures, and membership validation challenges unique to biosimilar and generic business models
Optimize operational execution across distribution channels while managing intricate chargeback processes and contract pharmacy relationships in an increasingly competitive landscape
Analyze how IRA implementation, Medicare Part D redesign, and emerging PBM policies are reshaping market access opportunities and contracting approaches for non-brand manufacturers
Future-proof your strategy by understanding shifting payor dynamics, regulatory requirements, and market entrant impacts on biosimilar and generic positioning
- Rodney Emerson - Vice President, Pricing & Contracts, Sandoz
- Understand how AIDS Drug Assistance Programs operate differently from typical 340B covered entities, focusing on unique rebate structures versus traditional chargeback models
- Navigate the specific requirements for manufacturers engaging with ADAP programs, including contract management, rebate processing, and program compliance
- Learn best practices for managing ADAP relationships, from initial program setup through ongoing operations and reporting requirements
- Cathy Burton-Meza - Associate Director, Government Rebates, Gilead Sciences
Join fellow senior leaders for an elevated lunch experience where you'll engage in facilitator-guided conversations on mission-critical topics impacting pharmaceutical manufacturers in 2025, including IRA implementation impacts, evolving PBM dynamics, state-level policy shifts, and strategic GTN management. This closed-door session provides a confidential environment for authentic dialogue and solution sharing.
Invitation-only gathering limited to 35 participants. Email katelyn.reichheld@informa.com for more details.
- Rosalind Davis - Director, Government Pricing and Contracts, CSL Vifor
- Kris Thiruvillakkat - Senior Director, Global Evidence Market Access & Pricing, CSL Behring
- Tyler J. Craddock - MBA, MT, National and Government Account Executive, Bluebird Bio
- Important developments in IRA implementation and litigation
- Update on 340B litigation and administrative actions on duplicate discounts and diversion
- Discussion of government efforts to rein in PBM abuses
- James Stansel - Executive Vice President, General Counsel and Corporate Secretary, PhRMA
- Review of the upcoming Pharmaceutical Compliance Program Guidance from the OIG
- Insights on the OIG's findings and trends from 340B audits of covered entities
- Perspective on the OIG's oversight role amidst evolving drug pricing and contracting practices
- Tanaz Dutia - Team Leader and Rapid Response Technical Expert, Office of Inspector General
- Edward Burley - Deputy Regional Inspector General, Office of Inspector General, U.S. Department of Health and Human Services